Bionomics is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system (CNS) disorders. Based in Adelaide, Australia with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • Chairman's Address Bionomics Annual General Meeting 2017

    15 November 2017

    Download PDF

  • CEO & Managing Director's Report to Shareholders

    15 November 2017

    Download PDF

  • BNC101 Phase 1 Clinical Trial Recruitment Completed

    31 October 2017

    Download PDF

LATEST CORPORATE PRESENTATION

Latest Analyst Report